Tigemonam is primarily utilized in the field of medicine as an antibiotic, specifically targeting bacterial infections. Its application is significant in treating infections caused by Gram-negative bacteria, which are often resistant to other antibiotics. Tigemonam works by inhibiting the synthesis of bacterial cell walls, leading to the destruction of the bacteria. This makes it particularly effective in managing urinary tract infections, respiratory tract infections, and certain types of sepsis. Its stability against beta-lactamase enzymes, which are produced by some bacteria to resist antibiotics, enhances its efficacy in clinical settings. Tigemonam is administered intravenously or intramuscularly, ensuring rapid distribution and action within the body. Its use is carefully monitored to minimize the risk of developing antibiotic resistance and to ensure optimal therapeutic outcomes.